Back to All Events

The Power of Big Data: Advancing Healthcare in the Electronic Era

  • JZ Young Lecture Theatre Anatomy Building University College London, Gower Street WC1E 6BT UK (map)

The field of computational biology has seen dramatic growth over the past few years. The significant advances in computing power are now being used to conduct data analytics, mathematical modelling and computational simulation, for an ever-increasingly diverse set of problems. With applications in genomics, neuroscience and medicine, we look to gain an understanding of its future implications with the emergence of Artificial Intelligence and Machine Learning and how this will disrupt and revolutionise both medicine and healthcare.


- 18:40-19:00 Speaker 1: Victor Dillard, COO, Desktop Genetics

- 19:00-19:20 Speaker 2: Alex Gutteridge, Director, Computational Biology GSK

- 19:20-19:40 Speaker 3: Dr. Parashkev Nachev, Senior Clinical Research, Inst. of Neurology

- 19:40-20:20 Q&A and panel discussion

- 20:20-21:00 Drinks and nibbles. Location: Malet Place, Engineering Building 1.20


Alex Gutteridge is a Director in the GSK Computational Biology group with responsibility for coordinating Computational Biology Neuroscience research. Alex has 7 years of experience as a Senior Scientist and Principal Scientist within the pharmaceutical industry. His current research focuses on modelling Human disease for drug discovery using informatics and genomics.


Dr. Parashkev Nachev is a Senior Clinical Research Associate at the Institute of Neurology and an honorary Consultant Neurologist at the National Hospital, Queen Square, London. His research deals primarily with translational aspects of cognitive and behavioural neurology, in particular with the development of novel methodology for distributed investigational and therapeutic devices.


Victor Dillard is Chief Operating Officer and Cofounder of Desktop Genetics. Desktop Genetics have raised $3.2 million to build A.I. that helps discover and treat the genetic causes of disease, by re-engineering the human genome. The founders sought to use CRISPR genome editing for research and clinical medicine with their London-based startup working at the intersection of tech and biotech.